Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. - Wikidata - awgldk - TriplyDB

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

http://www.wikidata.org/entity/Q37410508

about

Complement in Lupus Nephritis: New Perspectives Lupus nephritis: the evolving role of novel therapeutics A prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model.Lupus glomerulonephritis revisited 2004: autoimmunity and end-organ damage.CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis.Molecules Great and Small: The Complement System.Review: Complement and its regulatory proteins in kidney diseases.Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease Targeting of functional antibody-CD59 fusion proteins to a cell surface.The role of neutrophils and NETosis in autoimmune and renal diseases.Naja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr Mice Monoclonal antibodies and other biologic therapies.Pathogenesis of systemic lupus erythematosus (SLE).New therapies in development for autoimmune diseases: their rationale for combination treatment.Novel approaches in the treatment of lupus nephritis.Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice Novel therapeutic agents in clinical development for systemic lupus erythematosus.Therapy of systemic lupus erythematosus: a look into the future Complement and systemic lupus erythematosus.The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.Role for complement in development of Helicobacter-induced gastritis in interleukin-10-deficient mice.Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.Immunotherapy for autoimmune and inflammatory renal diseases.Complement involvement in kidney diseases: From physiopathology to therapeutical targeting Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus.A simple PCR-based method for the rapid genotyping of inherited fifth complement component (C5)-deficient mice.Pathogenic autoantibodies in lupus nephritis.Novel therapies in lupus nephritis.Theory, targets and therapy in systemic lupus erythematosus.Pathogenesis of lupus nephritis: an update.Complement and its breakdown products in SLE.Metabolic regulation of organelle homeostasis in lupus T cells Novel C5a regulators in inflammatory disease.Noninvasive Imaging of Activated Complement in Ischemia-Reperfusion Injury Post-Cardiac Transplant Preeclampsia: the death of Goliath.Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity, and late T cell interferon gamma: a possible initiating role of B cells.Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice.Complement deficiencies in humans and animals: links to autoimmunity.The role of complement in autoimmune renal disease.

P2860

Q26740491-35F8437E-2E5F-4A3D-8648-0D56ED45AB37 Q26998390-40F561FF-423D-449F-8930-92D6EF72692A Q30304046-1597058E-93C4-4583-BA27-B4DCA6FC118C Q30433903-A3029A1A-6AB9-4966-B8B1-06F5D11866D8 Q30453105-ACBEB44E-5963-4CE4-AE2B-ACD3B2575122 Q33419651-E185CC79-9012-4314-B2A2-BEA075B57019 Q33647738-FAE7FD88-B071-4E1C-8AD4-C47A82E4068A Q33769083-B854E1E6-DFD9-4570-8ADB-F23DE60C5C14 Q33834216-871C2F9A-5B15-42D1-BE2D-63D2456D9DCC Q33904653-B4E21FF0-49DD-49BD-8DBE-94BB0CF0E067 Q33908254-47AA646C-2FB4-47B7-B710-BEFCE6ABFA57 Q34227074-FFA93329-BCCE-4E02-B8CD-14FF23321C0C Q34291300-0A8397E7-DE32-40CF-A773-BC63B58FF8CF Q34309745-F3132D5B-4DBB-4BD4-BDB2-A90BA88EC4A1 Q34481499-60D2349B-DFF6-4EC5-840F-C8EE1DA556EF Q34537391-2F3A7DB4-CDB4-4013-BA32-AB0C133B7AB0 Q34704902-B855300B-5644-4289-8F1F-4186A9EFCFCF Q34731092-530171EF-2A11-44A2-A476-9209C93D93C6 Q34731255-1560DB02-3232-4E86-9D73-57096B67F631 Q34813568-8C3D0C14-E395-46D9-B527-E7DB90413674 Q34940884-3D963207-93CF-40C3-8AF4-10F2E08DFD1B Q35095565-D45721A6-DF02-4263-8447-3660629C3383 Q35144046-BAA9EAFD-4805-4060-ABC1-54A3B6E19705 Q35567841-39A83E0E-751D-4B1E-8D85-F5E681794A3C Q35824482-995B1321-D14A-4B68-9142-A702CA73C6CE Q35991991-A7D0BC0D-D96D-4791-B79A-1D6CCEB492B0 Q36054822-DA2CDD32-CB55-4901-9EE7-6BFB8A0DAC22 Q36054877-33D39B38-0164-46B8-9307-51D979D5ABA8 Q36088035-3E817654-B3BB-4363-9BF6-70F54FFA30F0 Q36118530-31AB05BE-2BD8-4C05-AEA9-4D7846F6F119 Q36171508-F935E5E9-DDD0-42BF-9E30-AD36275FADEF Q36177195-59366557-0E47-45F9-8685-1DFFB809422B Q36196446-2F63E805-4DD4-4A57-8908-1AD97B2FAC73 Q36302489-CD8B5A47-71AC-4AAC-BFDD-36A02190CE77 Q36376515-30168F35-68B3-4221-AEC3-A65644A9BCC4 Q36380633-FD7B2D97-92AB-49CF-886F-4010F77CCE60 Q36401591-84BDDA2E-7B57-473B-9018-D6854F15D5A8 Q36426921-4F6E5BE8-02F5-4B25-ACD7-840EA45C5B77 Q36572977-0242E7AD-4E98-4980-987D-A49C6346416C Q36573001-573F62AA-3A37-4988-BCD3-1C0BF28A465F

P2860

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

http://www.wikidata.org/entity/Q37410508

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 1996

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Amelioration of lupus-like aut ...... c for complement component C5.

@en

Amelioration of lupus-like aut ...... c for complement component C5.

@nl

type

label

Amelioration of lupus-like aut ...... c for complement component C5.

@en

Amelioration of lupus-like aut ...... c for complement component C5.

@nl

prefLabel

Amelioration of lupus-like aut ...... c for complement component C5.

@en

Amelioration of lupus-like aut ...... c for complement component C5.

@nl

P1433

Q37410508-61CAF62D-5A62-4779-A5A2-41B1B39717D8

P1476

Q37410508-26357D78-9F98-4358-A3CA-E8C5EAA43A1B

P2093

Q37410508-27958E95-6FEC-4523-ADA7-75C891B3427B

Q37410508-33043510-5527-4D1C-8EC1-C3B10CEE37F3

Q37410508-4A750C38-E000-411C-BA57-45D8E528EF5F

Q37410508-A57A1D2C-21EE-4172-9880-8269073D4406

Q37410508-CB38E552-DBDF-4425-BD46-5347F2FAE422

Q37410508-FD3F082D-AC82-4F0A-A226-1B05F21058FC

P2860

Q37410508-1C4E671A-904D-49F3-8D98-9B0209B8433E

Q37410508-2290CCE0-CC46-4226-9EE3-2ABCB5C763FA

Q37410508-22EF2D66-8EA2-446C-AD97-EB39CCF60B18

Q37410508-32E556EC-2E73-45E5-B182-3664B42E926E

Q37410508-38E7F162-1573-41B1-9FBE-5D7C04D6067B

Q37410508-47AB7EDE-98E2-48BD-9B50-86AB38EEF209

Q37410508-5A9B44A5-CFAA-419F-B50A-AE9709790BBC

Q37410508-67E877A3-8E45-4614-AFFF-9A60C04C752A

Q37410508-6DB5F5F6-4200-4F07-94DE-775C8E848CEC

Q37410508-9474FCE3-ED02-4812-B0C6-B489FB7506F3

P304

Q37410508-6298FA31-61FE-4333-9509-23B584AF2A2E

P31

Q37410508-F377B88C-966F-4984-82B1-E7FC53F753C5

P356

Q37410508-DC1A32A9-7CDC-41EA-84E3-66739C52C8BC

P407

Q37410508-0E833E9F-7367-406E-8E58-BCE3AE09E085

P433

Q37410508-2D7C6938-A7D2-499C-85E2-BC70C827DE5A

P478

Q37410508-31C0FECB-1816-4CFE-B9AF-FD5D1D8691DA

P577

Q37410508-2B9EEE57-FD02-4B08-894F-B5277A132275

P5875

Q37410508-719D4170-7DFF-4C63-854E-FE0C4A37E116

P698

Q37410508-29F0F97A-8B82-4982-8340-EEE67ADA843B

P921

Q37410508-0B4583AE-8B09-4216-B0AC-1089DBB6CA6A

P932

Q37410508-DDB38411-A9F8-45E7-8D83-BB16C04F5636

P356

PNAS.93.16.8563

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Amelioration of lupus-like aut ...... c for complement component C5.

@en

P2093

Chodera A

http://www.w3.org/2001/XMLSchema#string

Hu Q

http://www.w3.org/2001/XMLSchema#string

Madri JA

http://www.w3.org/2001/XMLSchema#string

Matis LA

http://www.w3.org/2001/XMLSchema#string

Rollins SA

http://www.w3.org/2001/XMLSchema#string

Wang Y

http://www.w3.org/2001/XMLSchema#string

P2860

C5A anaphylatoxin and its seven transmembrane-segment receptor

Inducible gene targeting in mice

Cytotoxic antibodies trigger inflammation through Fc receptors.

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.

Genetic analysis of the NZB contribution to lupus-like autoimmune disease in (NZB x NZW)F1 mice.

Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains

Induction of a cationic shift in IgG anti-DNA autoantibodies. Role of T helper cells with classical and novel phenotypes in three murine models of lupus nephritis

The molecular origin of anti-DNA antibodies.

Complement in the pathophysiology and diagnosis of human diseases.

P304

8563-8568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.93.16.8563

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

1996-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14491262

http://www.w3.org/2001/XMLSchema#string

P698

8710910

http://www.w3.org/2001/XMLSchema#string

P921

P932

38712

http://www.w3.org/2001/XMLSchema#string